Physician profile
Vikas Jogi
NPI 1053406546
$1,092.56
in general payments reported to CMS, 2019-2025
13 companies · $99.01 in 2025
The $99.01 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $467 · 2020: $39.99 · 2021: $99.88 · 2022: $169 · 2023: $27.67 · 2024: $190 · 2025: $99.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $317.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $225.79 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $208.83 | 2019-2022 | |
| Mylan Specialty L.P. | $161.61 | 2019 | |
| Abbott Laboratories | $144.52 | 2019 | |
| Insmed, INC. | $108.65 | 2020-2024 | Arikayce |
| Viiv Healthcare Company | $80.94 | 2021-2024 | Dovato |
| Gilead Sciences, INC. | $39.45 | 2021-2022 | |
| Melinta Therapeutics, LLC | $32.04 | 2024 | Orbactiv, Kimyrsa, Rezzayo |
| Genentech USA, INC. | $23.57 | 2019 | |
| Bioventus LLC | $22.64 | 2020 | |
| Mayne Pharma Commercial LLC | $18.26 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $13.59 | 2021 | |
| Grifols USA, LLC | $12.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikas Jogi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.